IHI or IYH or PSCH

Key Takeaways

• IHI offers targeted exposure to U.S. medical devices with 47 holdings and higher concentration (top 10 at ~75%), appealing for thematic investors but with elevated single-stock risk.
• IYH provides broad U.S. healthcare sector diversification across 103 holdings, balancing pharmaceuticals, biotech, and equipment at a competitive 0.38% expense ratio.
• PSCH focuses on small-cap healthcare firms with 77 holdings and the lowest expense ratio (0.29%), offering growth potential but higher volatility due to market cap tilt.
• All three are passive index trackers in healthcare, with IHI and IYH emphasizing large/mid-caps for stability, while PSCH targets smaller companies for differentiation.
• Concentration risk is highest in IHI, moderate in IYH due to caps, and lowest in PSCH, influencing risk-adjusted positioning in volatile markets.
• Cost efficiency favors PSCH, but IYH's broader exposure suits conservative allocations in the defensive healthcare theme.

Introduction

Comparing IHI, IYH, and PSCH highlights strategic variations within the resilient healthcare sector. IHI targets the medical devices subsector, IYH delivers comprehensive U.S. healthcare exposure including pharmaceuticals and providers, and PSCH zeroes in on small-cap healthcare names. These ETFs represent tiered approaches: niche thematic (IHI), broad sector (IYH), and size-based growth (PSCH). Amid aging demographics, innovation in biotech and devices, and steady sector demand, they offer distinct risk-return profiles. Investors weigh IHI's precision against IYH's diversification and PSCH's small-cap upside, especially as healthcare remains a defensive anchor in uncertain markets.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) tracks the Dow Jones U.S. Select Medical Equipment Index, focusing on U.S. companies manufacturing and distributing medical devices like imaging scanners and prosthetics. It holds 47 stocks, with top holdings including ISRG (Intuitive Surgical, ~16.5%), ABT (Abbott Laboratories, ~16%), SYK (Stryker, ~11%), EW (Edwards Lifesciences, ~5%), and IDXX (IDEXX Laboratories, ~4.7%). Sector allocation is nearly 100% healthcare equipment. The expense ratio is 0.38%. This passive, non-diversified fund rebalances quarterly, providing concentrated thematic exposure to innovation-driven medical technology firms.

iShares U.S. Healthcare ETF (IYH) Overview

The iShares U.S. Healthcare ETF (IYH) tracks the Russell 1000 Health Care RIC 22.5/45 Capped Gross Index, capturing large- and mid-cap U.S. healthcare equities with concentration caps for diversification. It features 103 holdings, led by LLY (Eli Lilly, ~14%), JNJ (Johnson & Johnson, ~10%), ABBV (AbbVie, ~6.6%), UNH (UnitedHealth Group, ~6.4%), and MRK (Merck, ~5%). Sector breakdown: pharmaceuticals (~36%), biotechnology (~22%), health care equipment (~17%), managed health care (~9%). Expense ratio is 0.38%. This passive fund uses capping to mitigate mega-cap dominance, offering balanced sector access.

Invesco S&P SmallCap Health Care ETF (PSCH) Overview

The Invesco S&P SmallCap Health Care ETF (PSCH) tracks the S&P SmallCap 600 Capped Health Care Index, targeting small-capitalization U.S. healthcare companies across biotech, services, and equipment. It includes 77 holdings, with top positions like MOH (Molina Healthcare, ~5.3%), GKOS (Glaukos, ~4.1%), KRYS (Krystal Biotech, ~3.9%), BTSG (BrightSpring Health Services, ~3.8%), and PTGX (Protagonist Therapeutics, ~3.1%). Nearly 100% healthcare allocation. Expense ratio is 0.29%, the lowest among the trio. This passive ETF rebalances quarterly with caps, emphasizing small-cap growth potential.

Industry and Thematic Landscape

The healthcare sector benefits from structural tailwinds like aging populations, rising chronic disease prevalence, and technological advances in devices and biotech. Capital flows favor defensive sectors amid economic uncertainty, with regulatory shifts (e.g., drug pricing reforms) and macroeconomic pressures (inflation impacting costs) influencing sentiment. Earnings trends show strength in pharmaceuticals and services, though devices face supply chain hurdles. Geopolitical tensions disrupt global supply chains for components, while sector risks include policy changes, litigation, and R&D failures. All three ETFs navigate this environment, with small-caps (PSCH) more sensitive to growth cycles and large-caps (IYH, IHI) offering stability.

Performance and Positioning Comparison

In recent months, broad healthcare (IYH) has shown trend consistency with lower volatility (3-year standard deviation ~14%), buoyed by mega-cap pharma stability. IHI, tied to devices, exhibited higher volatility (~18%) and deeper drawdowns in market cycles sensitive to innovation spending. PSCH displayed elevated volatility due to small-cap beta, with sharper swings but occasional outperformance in risk-on phases. Differences stem from structures: IHI's concentration amplifies device-specific moves, IYH's caps reduce mega-cap drag, and PSCH's size tilt heightens macro sensitivity. Risk-adjusted, IYH balances drawdowns, while PSCH suits momentum chasers.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to uncover healthcare ETF insights and beyond.

Tickeron AI Verdict

Tickeron’s AI favors IYH for its superior diversification (103 holdings), cost efficiency matching peers, stable momentum from broad exposure, and favorable risk-adjusted positioning via concentration caps. While PSCH offers value at lower fees and IHI provides thematic purity, IYH's balanced structure yields ~65% probability of outperformance in neutral-to-defensive environments, absent major small-cap rotations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations